乌司他丁在治疗危重症患者合并凝血功能障碍的临床疗效分析  

Analyze of the Clinical Efficacy of Ulinastatin in the Treatment of Critically Ill Patients with Coagulation Dysfunction

作　　者：肖丰[1] 陈松[2] 宋岩[1] 于慧超[1] 马玉东[1] 胡紫薇[3] 张晓娟[3] XIAO Feng;CHEN Song;SONG Yan;YU Huichao;MA Yudong;HU Ziwei;ZHANG Xiaojuan(ICU,Affiliated Central Hospital of Shenyang Medical College,Shenyang 110024,China;Department of Emergency,the First Affiliated Hospital of Hainan Medical College Haikou,Hainan 570102,China;ICU,the First Affiliated Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]沈阳医学院附属中心医院ICU,辽宁沈阳110024 [2]海南医学院第一附属医院急诊,海南海口570102 [3]中国医科大学附属第一医院ICU,辽宁沈阳110001

出　　处：《中国医药指南》2021年第22期55-56,共2页Guide of China Medicine

摘　　要：目的探讨分析乌司他丁在治疗危重症患者合并凝血功能障碍的临床疗效。方法将2017年3月至2020年3月规划为研究总时段,并以该时段中抽取在我院行危重症合并凝血功能障碍的97例患者作为本次研究样本对象。基于随机抽签规则,分为对照组和观察组。对照组48例,予常规治疗方式;观察组49例,予以乌司他丁治疗。比对分析两组对象凝血功能指标及治疗效果情况。结果经治疗,观察组对象凝血功能指标中,PLT(132.45±35.12)×10^(9)/L指标显著高于对照组(79.34±31.23)×10^(9)/L,D-二聚体(1.82±0.34)mg/L、PT(19.32±1.27)s及APTT(48.56±4.32)s指标则大幅度低于对照组[(3.12±0.55)mg/L,(22.10±2.34)s;(57.65±4.67)s],各项比对数据均差异显著(t=14.034、-7.861、7.292、9.954,均P<0.001);观察组对象治疗总有效率(95.92%)也显著高于对照组(81.25%),比对数据差异显著(χ^(2)=5.189,P=0.023)。结论在治疗危重症合并凝血功能障碍患者时应用乌司他丁治疗的效果显著,能有效改善患者的凝血功能指标,提高治疗有效率。Objective To explore and analyze the clinical efficacy of Ulinastatin in the treatment of critically ill patients with coagulation dysfunction.Methods The period from March 2017 to March 2020 was planned as the total period of the study,and 97 patients who underwent critically ill patients with coagulation dysfunction in our hospital during this period were selected as the sample objects for this study.Based on the random drawing rules,they are divided into the control group and the observation group.48 cases in the control group were treated with conventional treatment;49 cases in the observation group were treated with ulinastatin.Comparative analysis of the coagulation function indexes and treatment effects of the two groups of subjects.Results After treatment,among the coagulation function indexes of the observation group,PLT(132.45±35.12)×10^(9)/L was significantly higher than that of the control group(79.34±31.23)×10^(9)/L,D-dimer(1.82±0.34)mg/L,PT(19.32±1.27)s and APTT The index(48.56±4.32)s was significantly lower than the control group(3.12±0.55)mg/L,(22.10±2.34)s,(57.65±4.67)s,and the comparison data were significantly different(t=14.034,-7.861,7.292,9.954,all P<0.001);and the total effective rate of treatment in observation group(95.92%)is also significantly higher than that of the control group(81.25%),and the comparison data is significantly different(χ^(2)=5.189,P=0.023).Conclusion Ulinastatin has a significant effect in the treatment of critically ill patients with coagulation dysfunction.It can effectively improve the coagulation function of patients and increase the effective rate of treatment.

关 键 词：危重症患者 凝血功能障碍 乌司他丁 治疗效果 

分 类 号：R55[医药卫生—血液循环系统疾病]